Ranking Invest

ImmunoGen, Inc.

Segmento: Healthcare ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Indicadores Básicos

Valor de Mercado

$ 8.73 Bi

IVR

0.03

IVR2

-0.04

Índices de Previsibilidade

Faturamento

0.63

Lucro

0.80

Margem

0.76

Índices de Tendência

Faturamento

5.66

Lucro

-1.93

Margem

-0.31

Índices de Endividamento

DIV/PAT

-0.95

DIV/L4T

7.30

Dívida Líquida

-$ 533.42 Mi

Patrimônio Líquido

$ 561.60 Mi

L4T

-$ 73.07 Mi

MM4T

-50.67%

Dívidas
Dividendos
Cotação: $31.24

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre